119 related articles for article (PubMed ID: 28442372)
1. Long-term release and stability of pharmaceutical proteins delivered from solid lipid implants.
Vollrath M; Engert J; Winter G
Eur J Pharm Biopharm; 2017 Aug; 117():244-255. PubMed ID: 28442372
[TBL] [Abstract][Full Text] [Related]
2. New insights into process understanding of solid lipid extrusion (SLE) of extruded lipid implants for sustained protein delivery.
Vollrath M; Engert J; Winter G
Eur J Pharm Biopharm; 2018 Sep; 130():11-21. PubMed ID: 29913270
[TBL] [Abstract][Full Text] [Related]
3. Impact of implant composition of twin-screw extruded lipid implants on the release behavior.
Even MP; Bobbala S; Kooi KL; Hook S; Winter G; Engert J
Int J Pharm; 2015 Sep; 493(1-2):102-10. PubMed ID: 26188320
[TBL] [Abstract][Full Text] [Related]
4. Lipid extrudates as novel sustained release systems for pharmaceutical proteins.
Schulze S; Winter G
J Control Release; 2009 Mar; 134(3):177-85. PubMed ID: 19121347
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic studies on the release of lysozyme from twin-screw extruded lipid implants.
Sax G; Winter G
J Control Release; 2012 Oct; 163(2):187-94. PubMed ID: 22964391
[TBL] [Abstract][Full Text] [Related]
6. Study of stability and biophysical characterization of ranibizumab and aflibercept.
Moreno MR; Tabitha TS; Nirmal J; Radhakrishnan K; Yee CH; Lim S; Venkatraman S; Agrawal R
Eur J Pharm Biopharm; 2016 Nov; 108():156-167. PubMed ID: 27615995
[TBL] [Abstract][Full Text] [Related]
7. Injectable formulations for an intravitreal sustained-release application of a novel single-chain VEGF antibody fragment.
Asmus LR; Grimshaw JP; Richle P; Eicher B; Urech DM; Gurny R; Möller M
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):250-60. PubMed ID: 25779352
[TBL] [Abstract][Full Text] [Related]
8. Modulating release of ranibizumab and aflibercept from thiolated chitosan-based hydrogels for potential treatment of ocular neovascularization.
Moreno M; Pow PY; Tabitha TST; Nirmal S; Larsson A; Radhakrishnan K; Nirmal J; Quah ST; Geifman Shochat S; Agrawal R; Venkatraman S
Expert Opin Drug Deliv; 2017 Aug; 14(8):913-925. PubMed ID: 28643528
[TBL] [Abstract][Full Text] [Related]
9. Development of a Sustainable Release System for a Ranibizumab Biosimilar Using Poly(lactic-co-glycolic acid) Biodegradable Polymer-Based Microparticles as a Platform.
Tanetsugu Y; Tagami T; Terukina T; Ogawa T; Ohta M; Ozeki T
Biol Pharm Bull; 2017; 40(2):145-150. PubMed ID: 28154252
[TBL] [Abstract][Full Text] [Related]
10. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
11. Continuous release of Rh-interferon (alpha-2a from triglyceride implants: storage stability of the dosage forms.
Mohl S; Winter G
Pharm Dev Technol; 2006 Feb; 11(1):103-10. PubMed ID: 16544914
[TBL] [Abstract][Full Text] [Related]
12. Coaxial Electrospray of Ranibizumab-Loaded Microparticles for Sustained Release of Anti-VEGF Therapies.
Zhang L; Si T; Fischer AJ; Letson A; Yuan S; Roberts CJ; Xu RX
PLoS One; 2015; 10(8):e0135608. PubMed ID: 26273831
[TBL] [Abstract][Full Text] [Related]
13. Lipid-coated mannitol core microparticles for sustained release of protein.
Wang B; Friess W
Eur J Pharm Biopharm; 2018 Jul; 128():91-97. PubMed ID: 29684533
[TBL] [Abstract][Full Text] [Related]
14. Preparation of lipid aspirin sustained-release pellets by solvent-free extrusion/spheronization and an investigation of their stability.
Yan X; He H; Meng J; Zhang C; Hong M; Tang X
Drug Dev Ind Pharm; 2012 Oct; 38(10):1221-9. PubMed ID: 22713120
[TBL] [Abstract][Full Text] [Related]
15. A Novel Approach for Development of Intraocular Biodegradable Ranibizumab Implant: A Solution for Stability of Protein Activity.
Dadgar Pakdel F; Mirshahi A; Zahedi P; Mohammad K; Hemmati F; Dadgar Pakdel J; Nicknam MH; Abedin Dorkoosh F
Adv Pharm Bull; 2021 Sep; 11(4):632-642. PubMed ID: 34888210
[No Abstract] [Full Text] [Related]
16. Towards controlled release of BDNF--manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain.
Koennings S; Sapin A; Blunk T; Menei P; Goepferich A
J Control Release; 2007 Jun; 119(2):163-72. PubMed ID: 17428570
[TBL] [Abstract][Full Text] [Related]
17. Twin-screw extruded lipid implants containing TRP2 peptide for tumour therapy.
Even MP; Bobbala S; Gibson B; Hook S; Winter G; Engert J
Eur J Pharm Biopharm; 2017 May; 114():79-87. PubMed ID: 28104440
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device.
Lance KD; Bernards DA; Ciaccio NA; Good SD; Mendes TS; Kudisch M; Chan E; Ishikiriyama M; Bhisitkul RB; Desai TA
Drug Deliv Transl Res; 2016 Dec; 6(6):771-780. PubMed ID: 27178165
[TBL] [Abstract][Full Text] [Related]
19. Solid lipid extrusion of sustained release dosage forms.
Reitz C; Kleinebudde P
Eur J Pharm Biopharm; 2007 Sep; 67(2):440-8. PubMed ID: 17481868
[TBL] [Abstract][Full Text] [Related]
20. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery.
Zoubari G; Staufenbiel S; Volz P; Alexiev U; Bodmeier R
Eur J Pharm Biopharm; 2017 Jan; 110():39-46. PubMed ID: 27810471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
